Employees: 03 (2023.0)Legal category: 5485Size: PMECreation date: 2019-05-01 (7 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: NARBONNE (11100), Aude
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE HORTE NEUVE : revenue, balance sheet and financial ratios
PHARMACIE HORTE NEUVE is a French company
founded 7 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in NARBONNE (11100),
this company of category PME
shows in 2024 a net income positive of 274 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE HORTE NEUVE (SIREN 849981337)
Indicator
2024
2023
2022
2021
2020
2019
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
Net income
274 238 €
211 849 €
363 260 €
303 995 €
202 446 €
-8 251 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, PHARMACIE HORTE NEUVE generates positive net income of 274 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
274 238 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 123%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 41%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
123.225%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2020
2021
2022
2023
2024
Debt ratio
-51160.579
1263.968
488.103
250.271
178.723
123.225
Financial autonomy
-0.168
6.486
15.139
26.042
32.16
40.865
Repayment capacity
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
123.222024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Average-8 pts over 3 years
In 2024, the debt ratio of PHARMACIE HORTE NEUVE (123.22) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
40.87%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average+14 pts over 3 years
In 2024, the financial autonomy of PHARMACIE HORTE NEUVE (40.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE HORTE NEUVE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
Customer payment term (days)
0
0
0
149
0
0
Supplier payment term (days)
0
0
0
577
0
0
Positioning of PHARMACIE HORTE NEUVE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of PHARMACIE HORTE NEUVE is estimated at
3 828 565 €
(range 2 666 152€ - 5 727 752€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
2666k€3828k€5727k€
3 828 565 €Range: 2 666 152€ - 5 727 752€
NAF 5 année 2024
Valuation method used
Net Income Multiple
274 238 €
×
14.0x
=3 828 565 €
Range: 2 666 152€ - 5 727 753€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE HORTE NEUVE with other companies in the same sector:
Frequently asked questions about PHARMACIE HORTE NEUVE
What is the revenue of PHARMACIE HORTE NEUVE ?
The revenue of PHARMACIE HORTE NEUVE is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIE HORTE NEUVE profitable?
Yes, PHARMACIE HORTE NEUVE generated a net profit of 274 k€ in 2024.
Where is the headquarters of PHARMACIE HORTE NEUVE ?
The headquarters of PHARMACIE HORTE NEUVE is located in NARBONNE (11100), in the department Aude.
Where to find the tax return of PHARMACIE HORTE NEUVE ?
The tax return of PHARMACIE HORTE NEUVE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE HORTE NEUVE operate?
PHARMACIE HORTE NEUVE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart